TY - JOUR
T1 - Patterns of healthcare resource utilization in patients with sarcoidosis
T2 - A cross-sectional study
AU - Kampstra, Nynke A.
AU - van der Nat, Paul B.
AU - van Beek, Frouke T.
AU - Grutters, Jan C.
AU - van der Wees, Philip J.
N1 - Funding Information:
Support statement: This work was supported by The Netherlands Organisation for Health Research and Development (ZonMw) under project number 842001005. The funder had no role in the study design, data collection, analysis or decision of where to publish the manuscript.
Publisher Copyright:
© Mattioli 1885.
PY - 2021/10/13
Y1 - 2021/10/13
N2 - Background: Limited data are available on healthcare resource use and costs in patients with sarcoidosis; Objectives: The primary aim of this study was to describe cost-drivers of the top 1% and top ≥1-5% high-cost patients with sarcoidosis. The secondary aim was to compare costs of patients with and without fatigue complaints and to compare comorbidities. Methods: We conducted a retrospective observational cross-sectional study in 200 patients diagnosed with sarcoidosis. Hospital administrative databases were used to extract healthcare utilization on the individual patient level. Healthcare costs were categorized into nine groups. Results: Average total health care costs for the top 1% (n=22), top ≥1%-5% (n=88) and bottom 95% beneficiaries (n=90) were € 108.296, €53.237 and €4.817, respectively. Mean treatment time in days for the top 1%, top ≥1-5% and the random sample of the bottom 95% was 1688 days (±225), 1412 days (±367) and 775 days (±659), respectively. Mean annual costs for the top 1%, top ≥1-5% and the random sample of the bottom 95% are €51.082, €27.840 and €8.692, respectively. We identified three cost-drivers in the top 5% high-cost patients: 1) expensive medication, 2) intensive care and 3) costs made at the respiratory unit. Patients with and without fatigue showed to have comparable mean costs. High-cost patients were more likely to have multiple organs involved due to sarcoidosis. Conclusions: We identified expensive medication as the main cost-driver in the top 5% high-cost patients with sarcoidosis. The study findings can help to tailor interventions for improving the quality of care and reducing overall costs.
AB - Background: Limited data are available on healthcare resource use and costs in patients with sarcoidosis; Objectives: The primary aim of this study was to describe cost-drivers of the top 1% and top ≥1-5% high-cost patients with sarcoidosis. The secondary aim was to compare costs of patients with and without fatigue complaints and to compare comorbidities. Methods: We conducted a retrospective observational cross-sectional study in 200 patients diagnosed with sarcoidosis. Hospital administrative databases were used to extract healthcare utilization on the individual patient level. Healthcare costs were categorized into nine groups. Results: Average total health care costs for the top 1% (n=22), top ≥1%-5% (n=88) and bottom 95% beneficiaries (n=90) were € 108.296, €53.237 and €4.817, respectively. Mean treatment time in days for the top 1%, top ≥1-5% and the random sample of the bottom 95% was 1688 days (±225), 1412 days (±367) and 775 days (±659), respectively. Mean annual costs for the top 1%, top ≥1-5% and the random sample of the bottom 95% are €51.082, €27.840 and €8.692, respectively. We identified three cost-drivers in the top 5% high-cost patients: 1) expensive medication, 2) intensive care and 3) costs made at the respiratory unit. Patients with and without fatigue showed to have comparable mean costs. High-cost patients were more likely to have multiple organs involved due to sarcoidosis. Conclusions: We identified expensive medication as the main cost-driver in the top 5% high-cost patients with sarcoidosis. The study findings can help to tailor interventions for improving the quality of care and reducing overall costs.
KW - Costs
KW - Quality of care
KW - Sarcoidosis
UR - http://www.scopus.com/inward/record.url?scp=85102639889&partnerID=8YFLogxK
U2 - 10.36141/svdld.v37i3.9261
DO - 10.36141/svdld.v37i3.9261
M3 - Article
AN - SCOPUS:85102639889
SN - 1124-0490
VL - 37
SP - 1
EP - 8
JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases
JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases
IS - 3
M1 - e2020002
ER -